《大行報告》高盛:藥明康德(02359.HK)今年經調整非國際財務準則毛利率指引優預期
高盛發表報告指,藥明康德(02359.HK)去年第四季銷售達1,096萬元人民幣,按年升72%,經調整非國際財務準則(non-IFRS)計純利按年升71%至26億元人民幣,淨利潤率則達24%;同時,管理層指引今年收入增長按年升5%至7%,符合該行預期,而銷售指引亦意味按年升30%(撇除新冠商業化產品),另外經調整non-IFRS毛利指引按年升12%至14%,意味著毛利率有望改善260個基點,勝於該行預期。
該行又指,將公司今年、明年及2025年的各年每股盈測分別上調5.1%、1.3%及0.8%,同時維持其目標價為133元不變,以及其評級為「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.